116 related articles for article (PubMed ID: 22317799)
21. Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.
Li Y; Jortani SA; Ramey-Hartung B; Hudson E; Lemieux B; Kong H
Clin Chim Acta; 2011 Jan; 412(1-2):79-85. PubMed ID: 20854800
[TBL] [Abstract][Full Text] [Related]
22. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
[TBL] [Abstract][Full Text] [Related]
23. Genetic characterization of warfarin sensitivity in a population of cardiovascular patients on chronic anticoagulation.
Jorge E; Pêgo JM; Baptista R; Lourenço M; Marques I; Correia A; Monteiro P; Antunes F; Providência LA
Rev Port Cardiol; 2010 Dec; 29(12):1831-8. PubMed ID: 21428138
[TBL] [Abstract][Full Text] [Related]
24. Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.
Spohn G; Geisen C; Luxembourg B; Sittinger K; Seifried E; Bönig H
Mol Diagn Ther; 2011 Feb; 15(1):13-9. PubMed ID: 21469766
[TBL] [Abstract][Full Text] [Related]
25. Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array.
Pickering JW; McMillin GA; Gedge F; Hill HR; Lyon E
Am J Pharmacogenomics; 2004; 4(3):199-207. PubMed ID: 15174901
[TBL] [Abstract][Full Text] [Related]
26. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
[TBL] [Abstract][Full Text] [Related]
27. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese.
Zhu J; Zhang W; Li Y; Zhang W; Wang H; Zheng W; Wang C
Pharmacogenomics; 2010 Jan; 11(1):113-9. PubMed ID: 20017677
[TBL] [Abstract][Full Text] [Related]
28. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
[No Abstract] [Full Text] [Related]
29. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
30. Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.
Carlquist JF; McKinney JT; Nicholas ZP; Clark JL; Kahn SF; Horne BD; Muhlestein JB; May HT; Anderson JL
J Thromb Thrombolysis; 2008 Aug; 26(1):1-7. PubMed ID: 17661181
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
32. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
33. CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s).
Leung A; Huang CK; Muto R; Liu Y; Pan Q
Diagn Mol Pathol; 2007 Sep; 16(3):184-6. PubMed ID: 17721328
[TBL] [Abstract][Full Text] [Related]
34. Genes affecting warfarin response-interactive or additive?
Cavallari LH; Duarte JD
J Clin Pharmacol; 2015 Mar; 55(3):258-60. PubMed ID: 25385663
[TBL] [Abstract][Full Text] [Related]
35. Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation.
Yang J; Huang C; Shen Z; Miao L
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):23-9. PubMed ID: 21176721
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
39. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
40. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
